Biopharma Leaders Discuss Pharma’s Future at Pharmaceutical Strategic Alliances in New York

Bridgewater, NJ, August 8, 2011 - Elsevier Business Intelligence, the biopharma industry’s leading provider of strategic business intelligence and conferences, is hosting Windhover's 21st Pharmaceutical Strategic Alliances (PSA) September 21- 23, 2011 at the Millennium Broadway in New York, NY.

PSA is the only conference of its kind to provide direct access to such a diverse mix of pharma’s top talent. It’s an opportunity to hear first-hand from some of the industry’s most influential minds and leading experts. Chief Executive Officers Lamberto Andreotti of Bristol-Myers Squibb and George Scangos of Biogen Idec are just two of the speakers providing perspectives - and solutions - to the top challenges facing biopharma companies big and small.

Other leading experts from firms such as Pfizer, Johnson and Johnson, Roche and Merck will present information on other important topics facing the biopharma industry, including:

In addition to moderating strategic panels spanning R&D through commercialization, IN VIVO’s editorial team will also present an overview of current deal making trends, providing insights into top trends like academic alliances, creative deal structures, and the importance of innovation in today’s payor-dominated world.

"Pharmaceutical Strategic Alliances is a rare opportunity to provide a discussion of the various, most promising solutions to the industry’s toughest challenges. Call it a tool box for growth – and for those most in need, pharma’s survival kit," said Elsevier Business Intelligence’s Chris Morrison, Editor-in-Chief, Biopharma and Consumer Products.

To learn more about panel topics and keynote talks, visit: http://www.windhover.com/windhover/content/conferences/psaschedule11.asp
 

# # #

About Windhover Conferences and Elsevier Business Intelligence
Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of The Pink Sheet, IN VIVO: The Business & Medicine Report, PharmAsia News, The Tan Sheet”, Start-Up: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access, Elsevier Business Intelligence and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies’ products and services, please visit www.ElsevierBI.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Dianna Flanick
Vice President, Sales & Marketing
Elsevier Business Intelligence
+ 1 908 547 2141 
d.flanick@elsevier.com